Global biopharma leader Bristol Myers Squibb is heading into the 67th American Society of Hematology (ASH) Annual Meeting with a data blitz, unveiling 95 scientific disclosures that underscore major momentum across its next-generation hematology pipeline.

The company says new findings from its targeted protein degradation and cell therapy platforms show meaningful progress in multiple myeloma, lymphomas and a range of myeloid diseases.

Iberdomide: Early- and mid-stage studies continue to elevate iberdomide as a key contender in newly diagnosed multiple myeloma (NDMM). Updated cooperative group results show that maintenance therapy with the oral CELMoD continues to provide benefit following autologous stem-cell transplant.

Meanwhile, fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM, demonstrating “strong efficacy, safety, PK outcomes and sustained minimal residual disease (MRD) negativity.”

Golcadomide: Two years of follow-up reinforced the durability of the first-in-class lymphoma CELMoD golcadomide combined with R-CHOP in untreated aggressive B-cell lymphoma, delivering high complete response rates. Extended follow-up in relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) also showed “promising activity” for golcadomide with or without rituximab.

BCL6: Updated results for BMS-986458 — a bifunctional cereblon-dependent ligand-directed degrader (LDD) and the first of its kind — point to “encouraging efficacy and tolerability” in relapsed or refractory non-Hodgkin lymphoma (NHL).

Breyanzi: Longer-term data also bolstered the company’s cell therapy portfolio. Three-year findings from the Phase 2 TRANSCEND FL study confirmed sustained safety and strong efficacy for Breyanzi (lisocabtagene maraleucel) in third-line or later FL, even among high-risk patients. A four-year update from the Phase 3 TRANSFORM trial showed continued, durable benefit for second-line large B-cell lymphoma (LBCL).

Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, said the depth of data reflects the company’s commitment to reshaping treatment landscapes.

“Our goal is to deliver transformative medicines to help patients living with hematologic diseases and I am proud of the rich research we are showcasing at ASH this year,” he said.

“Specifically, the data we will present from our targeted protein degradation research platform, with multiple drugs such as iberdomide, mezigdomide, golcadomide and BCL6 LDD, may redefine the treatment paradigm for many blood cancers. In addition, new liso-cel data support long-lasting benefit to patients, while novel cell therapy pipeline assets expand our effort across diseases," he added.